Burning Rock to Present Validation Data of Magnis BR at the AMP Annual Meeting
October 29 2020 - 11:20PM
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or
“Burning Rock”) today announced that analytical validation data of
its fully-automated NGS library preparation platform, Magnis BR,
will be presented at the Association for Molecular Pathology (AMP)
2020 annual meeting, in a platform presentation (abstract number
TT04) on Thursday, November 19, 2020. Link to conference schedule
here.
Co-developed with Agilent Technologies (NYSE:A),
Magnis BR is a key component of Burning Rock’s strategy of
empowering hospitals to run NGS tests in-house with minimized lab
space and staff requirement, offering both tissue-based and
ctDNA-based test kits ranging from 4-gene to 520-gene panels. Its
fully automated “walk-away” 9-hour overnight library preparation
procedure enables hospitals to generate NGS reports in as quickly
as 3 days. As China’s first and only capture-based fully automated
NGS library preparation system, Magnis BR further strengthens
Burning Rock’s competitive position in the important in-hospital
testing market.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR),
whose mission is to guard life via science, focuses on the
application of next generation sequencing (NGS) technology in the
field of precision oncology. Its business consists of i) NGS-based
therapy selection testing for late-stage cancer patients, with the
leading market share in China and over 185,000 tissue and
liquid-based tests completed cumulatively, and ii) cancer early
detection, which has moved beyond proof-of-concept R&D into the
clinical validation stage.
For more information about Burning Rock, please
visit: www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements constitute “forward-looking”
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
“will,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates,” “target,” “confident” and similar
statements. Burning Rock may also make written or oral
forward-looking statements in its periodic reports to the SEC, in
its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Statements that are not
historical facts, including statements about Burning Rock’s beliefs
and expectations, are forward-looking statements. Such statements
are based upon management’s current expectations and current market
and operating conditions, and relate to events that involve known
or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock’s
control. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ
materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: pr@brbiotech.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024